Document Detail

Effects of rosuvastatin on vascular biomarkers and carotid atherosclerosis in lupus: a randomized, double-blind, placebo-controlled trial.
MedLine Citation:
PMID:  21309005     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To study the effect of rosuvastatin on vascular biomarkers and carotid intima-media thickness (IMT) in systemic lupus erythematosus (SLE).
METHODS: SLE patients with inactive disease and subclinical atherosclerosis were randomized in a double-blinded manner to receive either rosuvastatin (10 mg/day) or matching placebo (half in each group were also randomly allocated low-dose aspirin). After 12 months, treatment was unblinded. Patients treated with rosuvastatin and aspirin were continued on the same medications for another 12 months. Plasma levels of homocysteine, high-sensitivity C-reactive protein (hsCRP), soluble vascular cell adhesion molecule 1, P-selectin, and thrombomodulin were measured at baseline, 6 months, and 12 months. Measurement of carotid IMT was repeated at 24 months.
RESULTS: Seventy-two patients were studied (97% women, mean ± SD age 50.8 ± 9.7 years). Thirty-six patients were randomly assigned to each of the study arms (18 patients in each arm also received aspirin). Baseline clinical characteristics and medications were similar between the two groups. At 12 months, the mean low-density lipoprotein cholesterol (mean ± SD 2.62 ± 1.04 mmoles/liter to 1.69 ± 0.72 mmoles/liter; P < 0.001) and median hsCRP levels (1.26 mg/liter, interquartile range [IQR] 2.3 to 0.88 mg/liter, IQR 1.1; P = 0.02) decreased significantly in the rosuvastatin group. There was no significant change in homocysteine, and aspirin use did not influence the levels of the biomarkers studied. A subgroup analysis of patients with a Systemic Lupus Erythematosus Disease Activity Index score ≤2 revealed a significant decrease in hsCRP (1.20 mg/liter, IQR 2.3 to 0.92 mg/liter, IQR 1.1; P = 0.04) and thrombomodulin levels (0.76 ng/ml, IQR 1.2 to 0.67 ng/ml, IQR 1.0; P = 0.001) with rosuvastatin treatment. At 24 months, the IMT of the internal carotid arteries appeared to be decreased in patients treated with rosuvastatin, which was well tolerated.
CONCLUSION: In stable SLE patients, low-dose rosuvastatin leads to a significant reduction in hsCRP and thrombomodulin levels, which may possibly help to reduce cardiovascular risk.
Chi Chiu Mok; Chun Kwok Wong; Chi Hung To; Judy Po Shan Lai; Cheuk Sum Lam
Related Documents :
23526895 - Dynamic stabilization versus fusion for treatment of degenerative spine conditions.
21239675 - Water-assisted liposuction for body contouring and lipoharvesting: safety and efficacy ...
1880325 - Intranasal fluocortin butyl in patients with perennial rhinitis: a 12-month efficacy an...
21150665 - Sagittal alignment comparison of bryan disc arthroplasty with prodisc-c arthroplasty: a...
16950075 - The effect of a new multimodal perioperative anesthetic regimen on postoperative pain, ...
20543765 - Index and adjacent level kinematics after cervical disc replacement and anterior fusion...
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Arthritis care & research     Volume:  63     ISSN:  2151-4658     ISO Abbreviation:  Arthritis Care Res (Hoboken)     Publication Date:  2011 Jun 
Date Detail:
Created Date:  2011-06-01     Completed Date:  2011-08-02     Revised Date:  2011-12-09    
Medline Journal Info:
Nlm Unique ID:  101518086     Medline TA:  Arthritis Care Res (Hoboken)     Country:  United States    
Other Details:
Languages:  eng     Pagination:  875-83     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 by the American College of Rheumatology.
Tuen Mun Hospital, Hong Kong, China.
Data Bank Information
Bank Name/Acc. No.:
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Biological Markers / blood
C-Reactive Protein / metabolism
Carotid Artery Diseases / blood*,  complications,  drug therapy*
Double-Blind Method
Fluorobenzenes / therapeutic use*
Lupus Erythematosus, Systemic / blood*,  complications,  drug therapy*
Middle Aged
Pyrimidines / therapeutic use*
Sulfonamides / therapeutic use*
Thrombomodulin / blood
Reg. No./Substance:
0/Biological Markers; 0/Fluorobenzenes; 0/Pyrimidines; 0/Sulfonamides; 0/Thrombomodulin; 287714-41-4/rosuvastatin; 9007-41-4/C-Reactive Protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Determinants of incident and persistent finger joint pain during a 5-year follow up among female den...
Next Document:  Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring.